Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat

Cancer Research

Volumn 63, Issue 18, 2003, Pages 5902-5908

  Donald, Sarah ^a   Verschoyle, Richard D ^a   Greaves, Peter ^a   Gant, Timothy W ^a   Colombo, Tina ^b   Zaffaroni, Marco ^b   Frapolli, Roberta ^b   Zucchetti, Massimo ^b   D'Incalci, Maurizio ^b   Meco, Daniela ^c   Riccardi, Riccardo ^c   Lopez Lazaro, Luis ^d   Jimeno, Jose ^d   Gescher, Andreas J ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^d PHARMAMAR S A   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DEXAMETHASONE; TRABECTEDIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MEGADOSE; FEMALE; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; LIVER TOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP3A; DEXAMETHASONE; DIOXOLES; DOWN-REGULATION; DRUG INTERACTIONS; FEMALE; GENE EXPRESSION; ISOQUINOLINES; LIVER; LIVER DISEASES; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OXIDOREDUCTASES, N-DEMETHYLATING; RATS; RATS, INBRED F344; RATS, WISTAR; TETRAHYDROISOQUINOLINES;

EID: 0141731283     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Izbicka, E., Lawrence, R., Raymond, E., Eckhardt, G., Jimeno, J., Clark, G., and Von Hoff, D. D. In vitro antitumor activity of the novel marine agent ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Ann. Oncol., 9: 981-987, 1998.
2. Hendriks, H. R., Fiebig, H. H., Giavazzi, R., Langdon, S. P., Jimeno, J. M., and Faircloth, G. T. High antitumour activity of ET-743 against human tumour xenografts from melanoma, non-small cell lung cancer and ovarian cancer. Ann. Oncol., 10: 1233-1240, 1999.
3. Valoti, G., Nicoletti, M. I., Pellegrino, A., Jimeno, J., Hendriks, H., D'Incalci, M., Faircloth, G., and Giavazzi, R. Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin. Cancer Res., 4: 1977-1983, 1998.
4. Taamma, A., Misset, J. L., Riofrio, M., Guzman, C., Brain, E., Lopez-Lazaro, L., Rosing, H., Jimeno, J. M., and Cvitkovic, E. Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J. Clin. Oncol., 19: 1256-1265, 2001.
5. Delaloge, S., Yovine, A., Taamma, A., Riofrio, M., Brain, E., Raymond, E., Cottu, P., Goldwasser, F., Jimeno, J., Misset, J. L., Marty, M., and Cvitkovic, E. Ecteinascidin-743: A marine derived compound in advanced, pretreated sarcoma patients-preliminary evidence of activity. J. Clin. Oncol., 19: 1248-1255, 2001.
6. Van Kesteren, C., Cvitkovic, E., Taamma, A., Lopez-Lazaro, L., Jimeno, J. M., Guzman, C., Mathot, R. A. A., Schellens, J. H. M., Misset, J. L., Brain, E., Hillebrand, M. J. X., Rosing, H., and Beijnen, J. H. Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase 1 dose-finding study. Clin. Cancer Res., 6: 4725-4732, 2000.
7. Donald, S., Verschoyle, R. D., Edwards, R., Judah, D. J., Davies, R., Riley, J., Dinsdale, D., Lopez-Lazaro, L., Smith, A. G., Gant, T. W., Greaves, P., and Gescher, A. J. Hepatobiliary damage and changes in hepatic gene expression caused by the antitumor drug ecteinascidin 743 (ET-743) in the female rat. Cancer Res., 62: 4256-4262, 2002.
8. Pommier, Y., Kohlhagen, G., Bailly, C., Waring, M., Mazumder, A., and Kohn, K. W. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate ecteinascidia turbinata. Biochemistry, 35: 13303-13309, 1996.
9. Minuzzo, M., Marchini, S., Broggini, M., Faircloth, G. T., D'Incalci, M., and Mantovani, R. Interference of transcriptional activation by the anti-neoplastic drug ET-743. Proc. Natl. Acad. Sci. USA, 97: 6780-6784, 2000.
10. Jin, S., Gorfajn, B., Faircloth, G., and Scotto, K. W. Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc. Natl. Acad. Sci. USA, 97: 6775-6779, 2000.
11. Erba, E., Bergamaschi, D., Bassano, L., Damia, G., Ronzoni, S., Faircloth, G. T., and D'Incalci M. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur. J. Cancer, 37: 97-105, 2001.
12. Damia, G., Silvestri, S., Carrassa, L., Filiberti, L., Faircloth, G. T., Liberi, G., Foiani, M., and D'Incalci M. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int. J. Cancer, 92: 583-588, 2001.
13. Puchalski, T. A., Ryan, D. P., Garcia-Carbonero, R., Demetri, G. D., Butkiewuiocz, L., Harmon, D., Seiden, M. V., Maki, R. G., Lopez-Lazaro, L., Jimeno, J. M., Guzman, C., and Supko, J. G. Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity. Cancer Chemother. Pharmacol., 50: 309-319, 2002.
14. Sanderson, D. M. A note on glycerol formal as a solvent in toxicity testing. J. Pharm. Pharmacol., 11: 150-156, 1959.
15. Braunschweiger, P. G., and Schiffer, L. M. Growth kinetics of mammary tumor 13762 in rats previously cured by chemotherapy. J. Natl. Cancer Inst., 64: 671-674, 1980.
16. Pendergrast, W. J., Drake, W. P., and Mardiney, M. R. A proper sequence for the treatment of B16 melanoma: chemotherapy, surgery, and immunotherapy. J. Natl. Cancer Inst., 57: 539-544, 1976.
17. Talmadge, J. E., Key, M. E., and Hart, I. R. Characterization of a murine ovarian reticulum cell sarcoma of histiocytic origin. Cancer Res., 41: 1271-1280, 1981.
18. Formelli, F., and Cleris, L. Synthetic retinoid fenretinide is effective against a human ovarian carcinoma xenograft and potentiates cisplatin activity. Cancer Res., 53: 5374-5376, 1993.
19. Chen, T. R., Dorotinsky, C., Macy, M., and Hay, R. Cell identity resolved. Nature (Lond.), 340: 106, 1989.
20. Turton, N. J., Judah, D. J., Riley, J., Davies, R., Lipson, D., Styles, J. A., Smith, A. G., and Gant, T. W. Gene expression and amplification in breast carcinoma cells with intrinsic and acquired doxorubicin resistance. Oncogene, 20: 1300-1306, 2001.
21. Renwick, A. B., Lavignette, G., Worboys, P. D., Williams, B., Surry, D., Lewis, D. F. V., Price, R. J., Lake, B. G., and Evans, D. C. Evaluation of 7-benzoyloxy-4-trifluoromethylcoumarin, some other 7-hydroxy-4-trifluoromethylcoumarin derivatives and 7-benzyloxyquinolone as fluorescent substrates for rat hepatic cytochrome P450 enzymes. Xenobiotica, 31: 861-878, 2001.
22. Rosing, H. Hillebrand, M. J. X., Jimeno, J. M., Gomez, A., Floriano, P. Faircloth, G., Henrar, R. E. C., Vermorken, J. B., Cvitkovic, E., Bult, A., and Beijnen, J. H. Quantitative determination of Ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. J. Mass Spectrom., 33: 1134-1140, 1998.
23. Sparidans, R. W., Rosing, H., Hillebrand, M. J. X., Lopez-Lazaro, L., Jimeno, J. M., Manzanares, I., van Kesteren, C., Cvitkovic, E., van Oosterom, A. T., Schellens, J. H. M., and Beijnen, J. H. Search for metabolites of ecteinascidin 743, a novel marine-derived anti-cancer agent in man. Anti-Cancer Drugs. 12: 653-666, 2001.
24. Reid, J. M., Kuffel, M. J., Ruben, S. L., Morales, J. J., Rinehart, K. L., Squillace, D. P., and Ames, M. M. Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humans. Clin. Cancer Res., 8: 2952-2962. 2002.
25. Hari, P., and Srivastava, R. N. Pulse corticosteroid therapy with methylprednisolone or dexamethasone. Indian J. Pediatrics. 65: 557-560, 1998.
26. Sprung, C. L., Caralis, P. V., Marcial, E. H., Pierce, M., Gelbard, M. A., Long, W. M., Duncan, R. C., Tendler, M. D., and Karpf, M. The effect of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. N. Engl. J. Med., 311: 1137-1143, 1984.